טוען...
Effects of Abaloparatide-SC on Bone Mineral Density and Risk of Fracture in Postmenopausal Women Aged 80 Years or Older with Osteoporosis
OBJECTIVE: Advanced age is an important risk factor for fracture. The ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial showed that abaloparatide-SC increased bone mineral density and reduced the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosi...
שמור ב:
| הוצא לאור ב: | Menopause |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6015760/ https://ncbi.nlm.nih.gov/pubmed/29462094 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/GME.0000000000001080 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|